We are live on ! Find out more
OSTX icon

OS Therapies

26 hedge funds and large institutions have $2.49M invested in OS Therapies in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

68% more capital inflows, than outflows

Capital inflows: $941K | Capital outflows: $561K

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

0.1% more ownership

Funds ownership: 4.94% → 5.05% (+0.1%)

0% more funds holding

Funds holding: 26 → 26 (0)

Holders
26
Holders Change
–
Holders Change %
0%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OSTX Hedge Fund Activity: Q4 2025 in Review

26 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in OS Therapies (OSTX) for Q4 2025, worth a combined $2.49M — down 19% from $3.07M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new OSTX positions and 6 closed out — a net gain of 1 holder — while 8 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, adding an estimated $635K. The largest seller was Marshall Wace, cutting an estimated $160K.

  • 26 institutional investors held OS Therapies (OSTX) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $2.49M of OS Therapies stock for Q4 2025, down 19% quarter-over-quarter.
  • 7 funds opened new OS Therapies positions in Q4 2025 and 6 closed out, a net change of +1 holder.
  • The largest OS Therapies buyer in Q4 2025 was Vanguard Group, an estimated $635K added.
  • The largest OS Therapies seller in Q4 2025 was Marshall Wace, an estimated $160K sold.

Based on aggregated 13F filings for Q4 2025.